BioMedWire Stocks

Amazon Gives Prime Members Round-the-Clock Virtual Healthcare Access at Reduced Cost

Amazon, which was founded in 1994, has grown from an online bookstore that competed with Barnes & Noble and local booksellers to a conglomerate involved a range of industries. The company recently recorded a new milestone, launching virtual healthcare through its One Medical service.

This healthcare program can be accessed by members of Amazon Prime, either annually at $99 or monthly at $9. This is quite a steal, especially when compared to rates of nonmembers, which stand at $198 annually and $18 monthly. The One Medical service has different offerings, including its Treat Me Now feature, which offers guidance on common illnesses such as colds, infections and allergies, as well as 24/7 access to video chats with certified healthcare providers.

This virtual care program is the company’s latest move toward becoming a key player in the healthcare industry.

In 2019, the firm launched a virtual care platform for its employees dubbed Amazon Care. In 2021, the platform was made available to other employers. However, in late 2022, the company decided to withdraw it from the market, citing that the platform didn’t appeal to large enterprises as it wasn’t fully developed.

Despite this setback, however, Amazon bought out One Medical for almost $4 billion in early 2023. Later this year, it expanded the healthcare service to encompass around-the-clock telemedicine visits. In addition to this, it launched a monthly pharmaceutical subscription dubbed RxPass, which can be accessed by members of Amazon Prime.

Amazon is one among other companies also looking to expand their share of the healthcare market. Walmart, another retail giant, has also made progress toward becoming a major provider in this market. A few years ago, the retail giant began launching brick-and-mortar clinics across America, hoping to achieve its objective of becoming the neighborhood health destination in the country. In 2021, it also launched insulin drugs aimed at improving affordability of medicine for patients with diabetes.

Earlier in the year, Walmart announced that it planned to increase its clinics, hoping to add 28 new locations in 2024. Additionally, it was recently reported that the retail giant was in discussions to purchase majority stake in ChenMed. ChenMed is a primary care provider that mainly deals with seniors.

Walmart and Amazon are part of a larger pipeline of retailer-to-healthcare providers that has grown in the last few years. Pharmacy chains such as CVS and Walgreens are a few others that have greatly invested in becoming primary care providers.

Healthcare e-commerce platforms such as NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW) are also helping to popularize virtual healthcare, which could result in the majority of the population preferring to access all the healthcare services and products that they need via the internet.

NOTE TO INVESTORS: The latest news and updates relating to NextPlat Corp. (NASDAQ: NXPL) are available in the company’s newsroom at https://ibn.fm/NXPL

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

Adaptogenics Health Corp. (CSE: ADPT) Eyes Opportunities Beyond Standard Peptides as Policy Opens Pharmacy and Telehealth Channels

Disseminated on behalf of Adaptogenics Health Corp.and may include paid advertising. The federal government is…

21 hours ago

Quantum BioPharma Ltd. (NASDAQ: QNTM) Advances Broad Strategy Anchored by Science, Disciplined Growth

The scale of the need for neurological solutions is enormous; the World Health Organization reports…

22 hours ago

Scientists Develop Experimental Method Leveraging Ultrasound to Treat Brain Cancer

University of Virginia researchers have developed an experimental method that uses ultrasound to deliver therapeutic…

2 days ago

Earth Science Tech Inc. (ETST) Wins Through the Inherent Operating Leverage of Its ‘Conglomerate’ Business Model

Earth Science Tech’s ‘conglomerate’ business model has allowed it to leverage its internal tech stack,…

2 days ago

Adaptogenics Health Corp. (CSE: ADPT) Targets Supply, Verification, Traceability in Emerging Peptide Market

Disseminated on behalf of Adaptogenics Health Corp. and may include paid advertising. The movement toward…

3 days ago

Quantum BioPharma Ltd. (NASDAQ: QNTM) Draws ‘Men’s Fitness’ Spotlight as Unbuzzd Trial Shows Early Promise

Earlier this month, “Men’s Fitness,” reviewed the unbuzzd clinical trial and described the early study findings as…

3 days ago